Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

NCT01089595 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Novartis is ending their research program for Nilotinib in GIST.

Conditions

GIST
Metastatic Disease

Interventions

DRUG: Nilotinib
DRUG: Nilotinib with Imatinib

Sponsor

Fox Chase Cancer Center

Collaborators

[object Object]